X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $1.50 target price on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.15 EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $3.00 target price on shares of X4 Pharmaceuticals in a research report on Wednesday.

X4 Pharmaceuticals Stock Down 7.8 %

X4 Pharmaceuticals stock opened at $0.25 on Thursday. X4 Pharmaceuticals has a fifty-two week low of $0.24 and a fifty-two week high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The firm’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.52. The stock has a market cap of $43.42 million, a PE ratio of -2.78 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million. Research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insider Activity

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 202,663 shares of company stock worth $91,198. 1.62% of the stock is owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cantor Fitzgerald L. P. bought a new position in shares of X4 Pharmaceuticals in the fourth quarter worth $30,000. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals during the third quarter worth about $30,000. Atria Wealth Solutions Inc. bought a new position in X4 Pharmaceuticals in the 4th quarter worth about $44,000. Wells Fargo & Company MN increased its stake in X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after acquiring an additional 26,763 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares in the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.